Abstract: Provided herein are novel Glypican 3 (GPC3) antibodies or antigen binding fragments and GPC3/CD3 bispecific antibodies. The present application also provides chimeric antigen receptors comprising the antibodies or antigen-binding fragments, related CAR-T cells, and preparation methods and uses of the same. The present application further provides pharmaceutical compositions comprising GPC3 antibodies or antigen binding fragments, related GPC3/CD3 bispecific antibodies, related GPC3 CAR or CAR-T cells, and methods of treating cancer in a subject in need thereof by administering the Glypican 3 (GPC3) antibodies or antigen binding fragments, the bispecific antibodies, the chimeric antigen receptors, the CAR-T cells, or the pharmaceutical compositions. The cancers treated in accordance with the application include Glypican-3-positive cancers.

Abstract: An ROR1 CAR or ROR1/CD19 Dual CAR for the treatment of tumors. The T cells expressing ROR1 CAR or ROR1/CD19 Dual CAR can be stimulated by ROR1-positive or ROR1/CD19-positive cells, and have cytotoxicity against ROR1-positive or ROR1/CD19-positive cells.

Abstract: The present application provides novel fusion proteins for dephosphorylating proteins that regulate T cell activation through the TCR signaling pathway, nucleic acids encoding said proteins, vectors comprising said nucleic acids, compositions comprising said nucleic acids or vectors, host cells comprising said nucleic acids, vectors or compositions or related pharmaceutical compositions. The present application also provides methods for dephosphorylation of proteins that regulate T cell activation through the TCR signaling pathway of a cell, methods of producing a cell having dephosphorylated proteins that regulate T cell activation through the TCR signaling pathway (e.g. a CAR T cell having dephosphorylated Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) of endogenous CD3), methods of treating a disease, and methods of reducing or preventing GvHD in a subject associated with the administration of one or more CAR T-cells to the subject.

Abstract: The present application provides CLDN18.2 antibodies or antigen binding fragments thereof and related CLDN18.2/CD3 bispecific antibodies, as well as corresponding nucleic acids encoding same, vectors comprising such nucleic acids, host cells transfected with such nucleic acids or vectors. The present application further relates to isolated CLDN18.2 antibodies or antigen binding fragments thereof and related CLDN18.2/CD3 bispecific antibodies, pharmaceutical compositions comprising such antibodies, antigen binding fragments, bispecific antibodies, nucleic acids, vectors, or host cells and optionally a pharmaceutically acceptable carrier, and methods of treating cancer in a subject in need thereof by administering such pharmaceutical compositions. The cancers treated in accordance with the present application include CLDN18.2-positive cancers, such as, inter alia, gastric cancer and pancreatic cancer.

Abstract: Provided herein are novel Glypican 3 (GPC3) antibodies or antigen binding fragments and GPC3/CD3 bispecific antibodies. The present application also provides chimeric anti-gen receptors comprising the antibodies or antigen-binding fragments, related CAR-T cells, and preparation methods and uses of the same. The present application further provides pharmaceutical compositions comprising GPC3 antibodies or antigen binding fragments, related GPC3/CD3 bispecific antibodies, related GPC3 CAR or CAR-T cells, and methods of treating cancer in a subject in need thereof by administering the Glypican 3 (GPC3) antibodies or antigen binding fragments, the bispecific antibodies, the chimeric antigen receptors, the CAR-T cells, or the pharmaceutical compositions. The cancers treated in accordance with the application include Glypican-3-positive cancers.